Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Immune thrombocytopenia (ITP) World Impact Survey(I-WISh): impact of ITP on health-related quality of life

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Clinically-suspected cast nephropathy: A retrospective, national, real-world study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cerebral Oxygen Metabolism in Adults with Sickle Cell Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Protein phosphatase, Mg2+/Mn2+-dependent 1D (PPM1D) mutations in haematological cancer

    Research output: Contribution to journalReviewpeer-review

  3. Genome-Wide Circular RNA Expression Patterns Reflect Resistance to Immunomodulatory Drugs in Multiple Myeloma Cells

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. The Thioredoxin-Interacting Protein TXNIP Is a Putative Tumour Suppressor in Cutaneous T-Cell Lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Maysaa Abdulla
  • Peter Hollander
  • Tatjana Pandzic
  • Larry Mansouri
  • Susanne Bram Ednersson
  • Per-Ola Andersson
  • Magnus Hultdin
  • Maja Fors
  • Martin Erlanson
  • Sofie Degerman
  • Helga Munch Petersen
  • Fazila Asmar
  • Kirsten Grønbaek
  • Gunilla Enblad
  • Lucia Cavelier
  • Richard Rosenquist
  • Rose-Marie Amini
View graph of relations

The tumor cells in diffuse large B-cell lymphomas (DLBCL) are considered to originate from germinal center derived B-cells (GCB) or activated B-cells (ABC). Gene expression profiling (GEP) is preferably used to determine the cell of origin (COO). However, GEP is not widely applied in clinical practice and consequently, several algorithms based on immunohistochemistry (IHC) have been developed. Our aim was to evaluate the concordance of COO assignment between the Lymph2Cx GEP assay and the IHC-based Hans algorithm, to decide which model is the best survival predictor. Both GEP and IHC were performed in 359 homogenously treated Swedish and Danish DLBCL patients, in a retrospective multicenter cohort. The overall concordance between GEP and IHC algorithm was 72%; GEP classified 85% of cases assigned as GCB by IHC, as GCB, while 58% classified as non-GCB by IHC, were categorized as ABC by GEP. There were significant survival differences (overall survival and progression-free survival) if cases were classified by GEP, whereas if cases were categorized by IHC only progression-free survival differed significantly. Importantly, patients assigned as non-GCB/ABC both by IHC and GEP had the worst prognosis, which was also significant in multivariate analyses. Double expression of MYC and BCL2 was more common in ABC cases and was associated with a dismal outcome. In conclusion, to determine COO both by IHC and GEP is the strongest outcome predictor to identify DLBCL patients with the worst outcome.

Original languageEnglish
JournalAmerican Journal of Hematology
Volume95
Issue number1
Pages (from-to)57-67
Number of pages11
ISSN0361-8609
DOIs
Publication statusPublished - Jan 2019

ID: 59261263